公开(公告)号：US20250154510A1

公开(公告)日：2025-05-15

申请号：US18949317

申请日：2024-11-15

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Thomas G. GRAEBER ,  Chia-Chin CHEN ,  Owen WITTE ,  Jung Wook PARK

IPC: C12N15/113 ,  A61K45/06 ,  A61N5/10

Abstract: The current disclosure is centered on the hypothesis that a better understanding of the neuroendocrine transdifferentiation (NEtD) process will provide therapeutic targets for inhibiting this transition and thus improving standard of care therapies. Accordingly, the current disclosure provides for a method for treating cancer in a subject, the method comprising administering an inhibitor of a gene, wherein the gene comprises one or more of tenascin C (TNC), advillin (AVIL), S100A7, PPARG, LOX lysyl oxidase, KLF5, APOBEC2, FOSL1, FOXM1, hedgehog, RELA, p65, IKK complex, JAK, STAT, TFAP4, geminin, OCA-1, OCA-2, Nf-kB, Nf-kB family and associated regulators, angiogenesis regulators such as BMX kinase, TEK kinase, periostin (POSTN), and VEGF family, stress genes, such as the JUN/FOS family, a gene from the S100 family, and cell state regulators such as ASCL1, POU2F3, NEUROD1, ASCL2, and YAP1.